Human lung microvascular endothelial cells as potential alternatives to human umbilical vein endothelial cells in bio-3D-printed trachea-like structures.

BACKGROUND: We have been trying to produce scaffold-free structures for airway regeneration using a bio-3D-printer with spheroids, to avoid scaffold-associated risks such as infection. Previous studies have shown that human umbilical vein endothelial cells (HUVECs) play an important role in such structures, but HUVECs cannot be isolated from adult humans. The aim of this study was to identify alternatives to HUVECs for use in scaffold-free structures. METHODS: Three types of structure were compared, made of chondrocytes and mesenchymal stem cells with HUVECs, human lung microvascular endothelial cells (HMVEC-Ls), and induced pluripotent stem cell (iPSC)-derived endothelial cells. RESULTS: No significant difference in tensile strength was observed between the three groups. Histologically, some small capillary-like tube formations comprising CD31-positive cells were observed in all groups. The number and diameters of such formations were significantly lower in the iPSC-derived endothelial cell group than in other groups. Glycosaminoglycan content was significantly lower in the iPSC-derived endothelial cell group than in the HUVEC group, while no significant difference was observed between the HUVEC and HMVEC-L groups. CONCLUSIONS: HMVEC-Ls can replace HUVECs as a cell source for scaffold-free trachea-like structures. However, some limitations were associated with iPSC-derived endothelial cells.

[Association between hemostasis/coagulation-system parameters and clinicopathological factors in patients with primary lung cancer].

Previous studies have gradually clarified the relationship between cancer and blood coagulation disorder and its mechanism. Various studies have also reported the association between lung cancer and coagulation disorder. However, it is rare to measure most hemostasis/coagulation-system test parameters in clinical practice. In this study, we investigated the association of hemostasis/coagulation-system test parameters, such as the prothrombin time (PT), activated partial thromboplastin time (APTT), bleeding time, and platelet count, which are routinely measured as preoperative examination parameters in patients with lung cancer, with the histopathologically evaluated stage of lung cancer. Although the mean values of hemostasis/coagulation-system parameters in all subjects were within the normal ranges, there were significant changes with respect to the clinico-pathological factors, showing a specific tendency. In patients in whom the histopathological stage was advanced, the APTT was prolonged, or the platelet count was increased.

[Clinical analysis of resected pulmonary pleomorphic carcinoma].

OBJECTIVE: We studied the clinical feature of pulmonary pleomorphic carcinoma. PATIENTS: Of 1,073 patients underwent the resection of lung cancer in our hospital, 15 patients (1.4%) had primary pulmonary pleomorphic carcinoma. RESULTS: All patients were male, and the age was ranged from 57 to 83, mean 70.3 years old. The mean Brinkman Index was 1,028.7. Thirteen patients underwent the lobectomy with lymph node dissection, 1 patient underwent the bilobectomy with lymph node dissection, and the wedge resection was done for the remaining one. Four patients were in stage IA, 5 were in stage IB, 2 were in stage IIB, 1 was in stage IIIA, 2 were in stage IIIB, and 1 was in stage IV. Histologically, the vascular invasion was showed in 8 of 15 patients. The recurrence was occurred on 9 patients, from 1 to 20 months after surgery. The site of recurrence was lung in 3 patients, brain in 3, and abdominal lymphnodes, subcutaneous soft tissue of shoulder, carcinomatous pleurisy was observed in one patient each. The 1-year survival was 62.5% , and the 3-year survival was 46.9%. Conclusion : The prognosis for pulmonary pleomorphic carcinoma is poor. More meticulous follow up is necessary for patients with pleomorphic carcinoma than those with common non-small cell carcinoma.